Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Organisation › Details

Adocia S.A.

https://www.adocia.com

Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins. Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes. Worldwide, more than 366 million individuals are currently suffering from diabetes (with a forecast of 552 million individuals by 2030, i.e. a 51% increase, reaching 70% in emerging countries). 15% of these patients will develop a foot ulcer during their lifetime. The markets targeted by Adocia represent more than USD20 billion (USD17 billion for insulin therapy and USD3 billion for diabetic foot ulcer healing). Through its BioChaperone® state-of-the-art technological platform, Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public. Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer-healing product. Furthermore, Adocia is developing a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product. To be a global leader for the formulation of therapeutic proteins Based on its experience and recognized know-how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies. Adocia's therapeutic innovations aim at bringing solutions to a profoundly changing global pharmaceutical and economic context, characterized in particular by the increased prevalence and impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries. Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241, mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech index. *

	Start	2008-01-01 renamed
	Predecessor	Proteins & Peptides Management – PPM
	Industry	BioChaperone® technology
	Industry 2	therapeutic protein
	Person	Soula, Gérard (Adocia 201201 CEO + co-founder also founder of Flamel Technologies)
	Person 2	Danaguezian, Valérie (Adocia 201402 CFO)

	Region	Lyon
	Country	France
	Street	115 Avenue Lacassagne
	City	69003 Lyon
	Tel	+33-4-7261-0610
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	19,469,000 (revenu, operating (2017) 2017-12-31)
	Profit	-8,550,000 (2017-12-31)
	Cash	55,885,000 (2018-06-30)

		* Document for »About Section«:

		Record changed: 2024-02-12